Abstracts

There have been a number of interesting dialysis-related papers published recently. As always, our clinical specialists have been monitoring the publications and here is our summary of the papers we have found to be especially relevant.

Benefits of short daily HD reviewed

Improved quality of life was commonly seen across several studies when patients were on short daily haemodialysis (SDHD) therapy, with significant effects on physical as well as mental components. Improved control of hypertension was found, and reduction or even discontinuation of anti-hypertensive medication was possible in several cases.
Several studies also observed a reduction in parameters of cardiac hypertrophy. Improved nutrition and less need for erythropoietin to manage anaemia was also reported. Vascular access problems were similar, and data on hospitalisation rates were inconclusive.
The above information resulted from a systematic literature search on studies comparing SDHD to conventional HD with a minimum of ten patients in each group, resulting in a selection of 17 original articles for review. The majority of studies were performed in the USA or Italy, and all but one publication was less than ten years old. No randomised controlled trial was found.
Puñal J et al; Nephrol Dial Transplant 2008;23:2634-46
[http://ndt.oxfordjournals.org/cgi/content/abstract/23/8/2634]

RCT finds survival benefit with on-line HF therapy

A multi-centre study enrolled and randomised 64 patients to on-line predilution haemofiltration (HF) or to low-flux HD with a synthetic membrane and ultrapure dialysis fluid, and followed them for three years. Dropout was high as 23 patients withdrew for various reasons and 19 died during the study. 74% of the deaths had a cardiovascular cause.
The number of deaths was lower in the HF group, and a Cox regression analysis revealed an age-adjusted mortality odds ratio of 0.45 for on-line HF (95% cI: 0.21-0.99).
Hospitalisation events were similar in number, but average length of stay was four days shorter in the HF arm (p<0.001). Biochemical performance measures were similar at study end, except for lower urea Kt/V (1.07 vs. 1.42) and lower plasma 2 microglobulin level (24 vs. 37 mg/l) in the HF study arm.
Ref: Santoro A et al; Am J Kidney Dis 2008;52(3):507-18

Dialysis effects on vitamin levels investigated

Blood levels of water-soluble vitamins and homocysteine were investigated pre- and post-dialysis in 30 prevalent HD patients, half of whom were on a high-flux dialyser. All received multivitamin supplements routinely.
The change in blood level during dialysis correlated with the molecular weight, and for all vitamins the change was independent of membrane flux properties. Serum levels of folate and pyridoxal-5’-phosphate (PLP) were reduced by approximately 35%, while red blood cell folate levels were stable. Levels of thiamine and riboflavin were only reduced by 5-10%, and cobalamin was apparently unaffected by dialysis. The only difference seen between high- and low flux dialysis was in the homocystein reduction level, being 48% in the high-flux dialysis versus 37% in the low-flux group.
The authors recommend monitoring of vitamin status in dialysis patients regardless of which membrane type is used.
Ref: Heinz J et al; Nephrology 2008;13(5):384-9
[http://www3.interscience.wiley.com/journal/120124531/abstract]

The role of sodium level in dialysis fluid

The relations between the prescribed dialysis fluid sodium level and interdialytic weight gain and incidence of intradialytic hypotension was evaluated cross-sectionally in 2187 dialysis patients. A 140 mmol/l sodium level was used for 63% of patients while another 25% were dialysed against 138 mmol/l sodium.
While target dry weight was independent of the fluid sodium level the interdialytic weight gain was higher for patients on higher sodium, especially for the first dialysis of the week. Pre- and post-dialysis blood pressure data were similar between groups, except for a lower pre-dialysis pulse pressure in the low sodium group.
Symptomatic hypotension during dialysis occurred more frequently in patients on a higher sodium fluid. The authors consider their findings supportive of using a lower sodium concentration in the dialysis fluid.
Ref: Davenport A et al; Int J Artif Organs 2008;31(5):411-7
[http://www.ajkd.org/article/S0272-6386(08)00888-3/abstract]

The choice of dialyser matters

The recently presented initial data from the European Membrane Permeability Outcome (MPO) study strengthens the evidence that the middle molecule removal offered by high-flux dialysis membranes is clinically important.
This study enrolled only new patients to dialysis and focused on those at risk, characterised by having a serum albumin level below 4 g/dl. Patients randomised to start dialysis with a high-flux rather than a low-flux membrane showed a significant 37% risk reduction for all-cause death, after case mix adjustment. Diabetic dialysis patients also showed a significant risk reduction with high-flux membranes. We eagerly wait for the full MPO study data to be published.
Meanwhile the HEMO study, which reused dialysers to a large extent, failed to show a significant effect of membrane flux on all-cause mortality in the full study population of prevalent dialysis patients. However, patients already on dialysis for some years responded differently, with improved survival when randomised to a high-flux membrane.
Recently published post hoc analysis of the HEMO study data indicates that in these patients cardiac death is significantly associated with the amount of middle molecule removal, expressed as b2-microglobulin (b2m) Kt/V. Each 0.1 unit increase in b2m Kt/V was associated with a 7% risk reduction for cardiac death. A similar risk reduction, although not significant, was seen for infectious death.
A recent paper from US investigators highlighted that synthetic high-flux membranes may differ significantly in their capacity to remove middle molecules during HD treatments. In direct cross-over comparisons of different high-flux dialyser brands, they found small molecule removal to be mainly unaffected by membrane composition, while large molecule removal depended significantly on membrane composition and morphology. Polyflux® high-flux dialysers showed efficient removal of b2m as well as of other middle molecules (angiogenin, leptin and complement factor D).
Presentation by Prof. F.Locatelli during the ERA-EDTA Congress 2007.
Cheung AK, et al: Effects of high-flux hemodialysis on clinical outcomes: results of the HEMO study.
J Am Soc Nephrol. 2003;14(12):3251-63.
Cheung AK, et al: Association between serum 2-microglobulin level and infectious mortality in hemodialysis patients.
Clin J Am Soc Nephrol. 2008;3(1):69-77.

Long term follow-up of clotting incidence at reduced heparinisation with the AN69ST dialyser

In a single-centre study, 170 regular HD patients were randomised to be dialysed either with a heparinised AN69ST dialyser at a reduced dose of unfractionated heparin (2718±1388 U) or another dialyser at regular heparin dose (4800±1555 U). Over 15 months 26,626 sessions were provided with registration of clotting events.
Moderate clotting in the drip chamber was more frequently seen in the low-heparin group, as well as red patches in the dialyser at treatment end. However, massive clotting was similar in the two groups, with 1.4 events/1,000 sessions in the AN69ST/low heparinised group versus 1.6 events/1,000 sessions in the control group. Haemoglobin levels and erythropoietin needs remained stable in both groups.
Chanard J et al; Nephrol Dial Transplant 2008;23:2003-9 (http://ndt.oxfordjournals.org/cgi/content/abstract/23/6/2003)

Better survival with short daily HD

The five-centre experience of 415 patients from Europe and the USA starting a short daily HD programme between 1982 and 2005 has been reviewed.
Approximately two thirds of the patients were treated at home or in a self-care unit, while the others were treated in-centre. Weekly StdKt/V was 2.9±0.6 and 2.6±0.5 for the US and European patients respectively.
The five-year survival in these patients was 68%. When compared to matched patients in the USRDS registry, this was 2-3 times higher. The predicted time to 50% survival was 2-11 years longer in the short daily group.
Kjellstrand K et al; Nephrol Dial Transplant Advance Access May 5, 2008

Buttonhole cannulation practice reviewed

Expert opinions and historical insights into vascular access techniques for chronic haemodialysis have been gathered in an email discussion club. Contributors with experience in the buttonhole technique for patients with native arterio-venous fistulas found benefits to be easier cannulation, reduced pain and reduced aneurysm formation.
The paper discusses barriers to introducing the buttonhole technique and how to overcome these. Advice is provided on needling protocols, track formation and the preferred type of needle.
Murcutt G; Buttonhole cannulation: should this become the default technique for dialysis patients with native fistulas? Summary of the EDTNA/ERCA Journal Club discussion Autumn 2007. J Ren Care. 2008 Jun;34(2):101-8

A high ultrafiltration rate is associated with increased mortality risk

A prospective observational study in 287 haemodialysis patients has found that patients who died during the five-year observation period differed in several respects from those who survived, including a greater intra-dialytic weight gain.
In a Cox proportional hazard survival analysis, adjusting for several covariates, the body weight-adjusted UF rate appeared as an independent predictor of death (p<0.0001), while intra-dialytic weight gain did not. The authors conclude that longer or more frequent sessions should be considered in patients requiring high UF rates.
[Movilli E et al, Nephrol Dial Transplant. 2007;22(12):3547-52]

Clinical studies look at high-flux dialyzers

Two clinical studies performed by a team from Louisville, USA, benchmarked the performance of high-flux dialyzers. Comparing the Gambro Polyflux H series to Fresenius Optiflux and Polyflux S to the F series, the Polyflux filters respectively showed some 140% and 75% greater clearance for beta-2-microglobulin.
Other middle molecules were also better cleared by the Polyflux dialyzers, while urea and phosphate removals were similar. The paper emphasises that membranes made of apparently similar polymers may differ substantially in the removal of small protein uremic toxins.
[Ouseph R et al; Nephrol Dial Transplant Advance Access Dec 21, 2007]

Beta-2-microglobulin serum level is associated with infectious mortality in dialysis patients

A recent analysis of data from 1813 chronic HD patients participating in the HEMO study found that for each 10 mg/l greater serum b2m level the risk for infectious death increased by 21%, which was statistically highly significant. The effect was not dependant on how long patients had been on dialysis.
This data supports the use of high-flux dialyzers to increase the removal of middle molecules and the use of serum b2m level as marker of uremic toxicity.
[Cheung AK et al, Clin J Am Soc Nephrol 2008;3:69-77]

Cardiovascular death rate is less in patients treated with on-line HDF

A positive assessment of the effects of on-line HDF is an outcome of a prospective observational study of all chronic HD patients in the northwest part of the Tuscany region, Italy.
During a 30-month follow-up, all patients on on-line HDF treatment (17% of all) were compared to those on HD (56%) or low-volume HDF with bagged reinfusion fluid (27%). Both HDF groups showed better survival rates than the regular HD group.
Inflammatory markers (CRP, IL-6) also correlated significantly with mortality rates. Patients on on-line HDF showed significantly lower IL-6 levels than the other groups.
[Panichi V et al, Nephrol Dial Transplant. 2008; Advance Access Feb 27, 2008]

American researchers investigate allergic reactions in haemodialysis patients

An outbreak of acute allergic-type reactions in US haemodialysis patients is being investigated by the US Centers for Disease Control and Prevention (CDC). In a report on their ongoing investigation, CDC states, 65 confirmed or probable cases from mid November 2007 to mid January 2008. The following signs and symptoms are reported:

  • Generalised or localised sensations of warmth, numbness or tingling of the extremities.
  • Difficulty in swallowing.
  • Shortness of breath/audible wheezing/chest tightness.
  • Low blood pressure/tachycardia.
  • Nausea/vomiting.

One factor being investigated is receipt of a certain batch of heparin, but other exposures have not been ruled out as potential causes of the reactions.
[Centers for Disease Control and Prevention (CDC), MMWR Morb Mortal Wkly Rep. 2008 Feb 8;57(5):124-5]

A high ultra filtration rate is associated with increased mortality risk

A prospective observational study in 287 haemodialysis patients has found that patients who died during the five-year observation period differed in several respects from those who survived, including a greater intra-dialytic weight gain.
In a Cox proportional hazard survival analysis, adjusting for several covariates, the body weight-adjusted UF rate appeared as an independent predictor of death (p<0.0001), while intra-dialytic weight gain did not. The authors conclude that longer or more frequent sessions should be considered in patients requiring high UF rates.
[Movilli E et al, Nephrol Dial Transplant. 2007;22(12):3547-52]

Clinical studies look at high-flux dialyzers

Two clinical studies performed by a team from Louisville, USA, benchmarked the performance of high-flux dialyzers. Comparing the Gambro Polyflux H series to Fresenius Optiflux and Polyflux S to the F series, the Polyflux filters respectively showed some 140% and 75% greater clearance for beta-2-microglobulin.

Other middle molecules were also better cleared by the Polyflux dialyzers, while urea and phosphate removals were similar. The paper emphasises that membranes made of apparently similar polymers may differ substantially in the removal of small protein uremic toxins.
[Ouseph R et al; Nephrol Dial Transplant Advance Access Dec 21, 2007]

Beta-2-microglobulin serum level is associated with infectious mortality in dialysis patients

A recent analysis of data from 1813 chronic HD patients participating in the HEMO study found that for each 10 mg/l greater serum b2m level the risk for infectious death increased by 21%, which was statistically highly significant. The effect was not dependant on how long patients had been on dialysis.
This data supports the use of high-flux dialyzers to increase the removal of middle molecules and the use of serum b2m level as marker of uremic toxicity.
[Cheung AK et al, Clin J Am Soc Nephrol 2008;3:69-77]

Cardiovascular death rate is less in patients treated with on-line HDF

A positive assessment of the effects of on-line HDF is an outcome of a prospective observational study of all chronic HD patients in the northwest part of the Tuscany region, Italy. During a 30-month follow-up, all patients on on-line HDF treatment (17% of all) were compared to those on HD (56%) or low-volume HDF with bagged reinfusion fluid (27%). Both HDF groups showed better survival rates than the regular HD group. Inflammatory markers (CRP, IL-6) also correlated significantly with mortality rates. Patients on on-line HDF showed significantly lower IL-6 levels than the other groups.
[Panichi V et al, Nephrol Dial Transplant. 2008; Advance Access Feb 27, 2008]

American researchers investigate allergic reactions in haemodialysis patients

An outbreak of acute allergic-type reactions in US haemodialysis patients is being investigated by the US Centers for Disease Control and Prevention (CDC). In a report on their ongoing investigation, CDC states, 65 confirmed or probable cases from mid November 2007 to mid January 2008. The following signs and symptoms are reported:

  • Generalised or localised sensations of warmth, numbness or tingling of the extremities.
  • Difficulty in swallowing.
  • Shortness of breath/audible wheezing/chest tightness.
  • Low blood pressure/tachycardia.
  • Nausea/vomiting.

One factor being investigated is receipt of a certain batch of heparin, but other exposures have not been ruled out as potential causes of the reactions.
[Centers for Disease Control and Prevention (CDC), MMWR Morb Mortal Wkly Rep. 2008 Feb 8;57(5):124-5]